Arcturus Therapeutics (ARCT) said Friday the European Commission granted marketing authorization for Kostaive, a self-amplifying mRNA COVID-19 vaccine for individuals aged 18 and above.
The biotechnology company said Kostaive is the first self-amplifying mRNA COVID vaccine to receive European Commission clearance and is currently marketed in Japan against the disease.
Kostaive showed "superior" immunogenicity and maintained antibody levels for up to 12 months post-vaccination compared to traditional mRNA vaccines, the company said.
The company also said that the approval follows a favorable opinion from the Committee for Medicinal Products for Human Use of the European Medicines Agency on Dec. 12 and is valid across all European countries.
The company's shares were up 2.1% in recent premarket activity.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.